Pinnacle Bancorp Inc. Increases Position in Pfizer Inc. (NYSE:PFE)

Pinnacle Bancorp Inc. lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 19.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 31,909 shares of the biopharmaceutical company’s stock after acquiring an additional 5,111 shares during the quarter. Pinnacle Bancorp Inc.’s holdings in Pfizer were worth $885,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of the stock. Addenda Capital Inc. grew its stake in shares of Pfizer by 0.5% during the first quarter. Addenda Capital Inc. now owns 199,272 shares of the biopharmaceutical company’s stock worth $5,530,000 after purchasing an additional 947 shares in the last quarter. Sendero Wealth Management LLC grew its stake in shares of Pfizer by 19.0% during the first quarter. Sendero Wealth Management LLC now owns 10,899 shares of the biopharmaceutical company’s stock worth $302,000 after purchasing an additional 1,738 shares in the last quarter. Register Financial Advisors LLC grew its stake in shares of Pfizer by 87.1% during the first quarter. Register Financial Advisors LLC now owns 56,129 shares of the biopharmaceutical company’s stock worth $1,558,000 after purchasing an additional 26,131 shares in the last quarter. Capital Asset Advisory Services LLC grew its stake in shares of Pfizer by 19.9% during the first quarter. Capital Asset Advisory Services LLC now owns 87,145 shares of the biopharmaceutical company’s stock worth $2,323,000 after purchasing an additional 14,492 shares in the last quarter. Finally, Indiana Trust & Investment Management CO grew its stake in shares of Pfizer by 2.4% during the first quarter. Indiana Trust & Investment Management CO now owns 16,934 shares of the biopharmaceutical company’s stock worth $470,000 after purchasing an additional 400 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 0.7 %

NYSE PFE opened at $27.99 on Friday. The stock has a market capitalization of $158.61 billion, a P/E ratio of -466.42, a P/E/G ratio of 1.09 and a beta of 0.70. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $37.80. The firm has a 50-day moving average price of $27.90 and a 200 day moving average price of $27.69. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66.

Pfizer (NYSE:PFE) last issued its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The company had revenue of $14.88 billion during the quarter, compared to analysts’ expectations of $13.87 billion. During the same period last year, the company posted $1.23 earnings per share. The firm’s quarterly revenue was down 19.5% compared to the same quarter last year. Equities research analysts expect that Pfizer Inc. will post 2.38 EPS for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be issued a $0.42 dividend. The ex-dividend date is Friday, July 26th. This represents a $1.68 dividend on an annualized basis and a yield of 6.00%. Pfizer’s dividend payout ratio (DPR) is presently -2,799.53%.

Analyst Ratings Changes

A number of equities analysts recently commented on PFE shares. BMO Capital Markets reiterated an “outperform” rating and set a $36.00 target price (up previously from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Morgan Stanley upped their price objective on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research note on Thursday, May 2nd. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Wednesday. Ten analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $35.86.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.